• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Lys Therapeutics Secures $5M MJFF Grant for Parkinson’s Treatment

by Jasmine Pennic 09/26/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Lys Therapeutics, a French biotechnology company, has announced a $5M grant award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). 

– The significant funding, part of MJFF’s Therapeutic Pipeline Program, will accelerate the clinical development of LYS241, a first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders. The grant will support the completion of preclinical development and the launch of first-in-human clinical trials.

Breakthrough Mechanism Targeting the Blood-Brain Barrier

LYS241 is a novel therapeutic approach designed to target the pathological mechanisms associated with blood-brain barrier (BBB) dysfunction, which is a central process in many neurological diseases. BBB impairment allows toxic molecules and inflammatory cells to enter the central nervous system, leading to neuroinflammation and neuronal death.

Unlike conventional therapies that must cross the BBB, LYS241 works from within the blood vessels. Specifically, it is designed to block the interaction between tissue plasminogen activator (tPA) and the NMDA receptor (NMDAr) in the vascular compartment. By doing so, it restores BBB integrity and interrupts the cascade of events, including dopaminergic neuron degeneration, that leads to neurodegeneration. This approach targets a fundamental cause of disease progression instead of limiting treatment to symptom control.

“Pipeline-in-a-Drug” Potential

The MJFF award is a strong validation of the science behind LYS241. It supports Lys Therapeutics’ “pipeline-in-a-drug” strategy—developing LYS241 for multiple neurological diseases driven by BBB dysfunction and neuroinflammation. Beyond Parkinson’s disease, LYS241 has demonstrated potent disease-modifying effects in validated preclinical models of multiple system atrophy, ischemic stroke, and multiple sclerosis.

“We are honored by the continued trust of The Michael J. Fox Foundation. This grant is both a strong validation of the science behind LYS241 and a powerful catalyst for our development program. It enables us to move with confidence toward clinical evaluation, with the goal of offering patients a truly novel therapeutic option.” said Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Aging Care, neurological conditions, neuropsychiatric disorders

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |